Valproate not to be used in female children and women of childbearing potential

Pharmaceuticals supplier, Sanofi, has issued a reminder to health professionals on the use of Valproate in female children and women of childbearing potential unless other treatments are ineffective or not tolerated. Further, Valproate is contraindicated in the following situations:

Treatment of epilepsy

• In pregnancy unless there is no suitable alternative treatment
• In women of childbearing potential, unless the physician has provided information regarding the potential effects of Valproate during pregnancy and recommendations on the use of valproate

Treatment of mania

• In pregnancy
• In women of childbearing potential, unless the physician has provided information regarding the potential effects of Valproate during pregnancy and the recommendations on the use of valproate

Valproate guide for health professionals

A booklet by Sanofi to provide information to prescribers on the risks associated with the use of Valproate during pregnancy.

Valproate patient guide

A booklet by Sanofi to provide information to female patients on the risks associated with taking Valproate whilst pregnant.

More information on Valproate – Sanofi

www.sanofi.eom.au/valproate

Call Sanofi Medical Information on 1800 818 806.